Veeva Systems Inc. VEEV, on Thursday, announced that Direct Data API is now included for no additional license fee as part of Veeva Vault Platform. This is expected to enable AI innovation in the life sciences industry.

It is worth noting that Veeva Direct Data API is a new class of API that makes Veeva Vault data accessible at a significantly faster pace, unlike traditional APIs, and is transactionally sound across large datasets.

The latest inclusion of the Direct Data API is expected to make the Veeva Vault Platform more attractive to the life sciences industry, thus boosting its overall business.

Likely Trend of VEEV Stock Following the News

Following the announcement, shares of the company lost nearly 3.6% till yesterday’s closing.

Historically, the company has gained a top-line boost from its various product innovations. Although the latest announcement is likely to be beneficial for VEEV’s top-line growth going forward, the stock declined overall.

Veeva Systems currently has a market capitalization of $36.39 billion. It has an earnings yield of 3.1%, favorable than the industry’s negative yield. In the last reported quarter, VEEV delivered an earnings surprise of 10.8%.

Significance of Veeva Systems’ Latest Announcement

Per Veeva Systems, with the ability to easily extract full or incremental Vault data reliably at very high speeds, customers and partners will be able to use the Direct Data API to power AI applications, analytics and system-to-system integrations. Direct Data API will also include connectors for Amazon Redshift, Snowflake, Databricks and Power BI later this year.

Management believes that the company’s breakthrough technology, Veeva Direct Data API, will likely enable new types of applications and integrations. Management also continued that as it is expected to provide customers and partners with easy and reliable access to large volumes of Veeva Vault data, this will likely fuel innovation in AI and analytics throughout the industry.

Industry Prospects in Favor of VEEV

Per a report by Precedence Research, the global AI in life sciences market is estimated to be $2.73 billion in 2025 and is anticipated to reach $13.89 billion by 2034 at a CAGR of approximately 19.8%. Factors like the growing demand for therapeutics to treat complex diseases and the growing need for improving productivity are likely to drive the market.

Given the market potential, the latest inclusion of Veeva Direct Data API in Vault Platform is expected to be a significant milestone for Veeva Systems and boost its business.

Veeva Systems’ Notable Developments

In January, Veeva Systems announced a product partnership with Zifo to aid biopharmas modernize quality control (QC) operations. By combining Veeva LIMS with Zifo's data integration and management platform, qcKen, companies will be able to import data directly from any source document or other LIMS into Veeva LIMS. This integration is expected to simplify master data configuration during LIMS implementation and site deployment, making it easier for companies to advance beyond legacy QC systems.

Veeva Systems, in December 2024, announced the newest release of Vault CRM Suite, Vault CRM Campaign Manager.

The same month, Veeva Systems announced its third-quarter fiscal 2025 results, wherein it registered a robust uptick in total revenues and subscription services revenues. At the same time, management announced three new AI innovations planned for availability in late 2025. This includes CRM Bot (a GenAI assistant) and Voice Control (a voice interface leveraging Apple Intelligence), both in Vault CRM. VEEV also announced MLR Bot for Vault PromoMats, which uses a Veeva Systems-hosted large language model to speed review and approval by checking the quality and content of promotional materials.

VEEV’s Share Price Performance

Shares of the company have lost 1.2% in the past year compared with the industry’s 11.3% decline. The S&P 500 has gained 16.2% in the same time frame.

Image Source: Zacks Investment Research

Veeva Systems’ Zacks Rank & Stocks to Consider

Currently, VEEV carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the broader medical space are Cardinal Health, Inc. CAH, ResMed Inc. RMD and Boston Scientific Corporation BSX.

Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 10.7%. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Cardinal Health’s shares have gained 14.4% against the industry’s 1.1% decline in the past year.

ResMed, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 16%. RMD’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.9%.

ResMed has gained 31.2% compared with the industry’s 14.2% growth in the past year.

Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.3%.

Boston Scientific’s shares have rallied 56.5% compared with the industry’s 14.2% growth in the past year.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Boston Scientific Corporation (BSX) : Free Stock Analysis Report

Cardinal Health, Inc. (CAH) : Free Stock Analysis Report

ResMed Inc. (RMD) : Free Stock Analysis Report

Veeva Systems Inc. (VEEV) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research